Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

BACKGROUND: Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA). However, few studies on the efficacy of this biologic in...

Descripción completa

Detalles Bibliográficos
Autores principales: Numata, Takanori, Miyagawa, Hanae, Nishioka, Saiko, Okuda, Keitaro, Utsumi, Hirofumi, Hashimoto, Mitsuo, Minagawa, Shunsuke, Ishikawa, Takeo, Hara, Hiromichi, Araya, Jun, Kuwano, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398222/
https://www.ncbi.nlm.nih.gov/pubmed/32746787
http://dx.doi.org/10.1186/s12890-020-01248-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398222/
https://www.ncbi.nlm.nih.gov/pubmed/32746787
http://dx.doi.org/10.1186/s12890-020-01248-x

Ejemplares similares